Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

Wiley full text link Wiley Free PMC article
Full text links

Actions

Share

.2022 Jun;31(6):670-679.
doi: 10.1002/pds.5428. Epub 2022 Mar 24.

Proton pump inhibitors may enhance the risk of citalopram- and escitalopram-associated sudden cardiac death among patients receiving hemodialysis

Affiliations

Proton pump inhibitors may enhance the risk of citalopram- and escitalopram-associated sudden cardiac death among patients receiving hemodialysis

Magdalene M Assimon et al. Pharmacoepidemiol Drug Saf.2022 Jun.

Abstract

Purpose: Polypharmacy is common in the hemodialysis population and increases the likelihood that patients will be exposed to clinically significant drug-drug interactions. Concurrent use of proton pump inhibitors (PPIs) with citalopram or escitalopram may potentiate the QT-prolonging effects of these selective serotonin reuptake inhibitors through pharmacodynamic and/or pharmacokinetic interactions.

Methods: We conducted a retrospective cohort study using data from the U.S. Renal Data System (2007-2017) and a new-user design to examine the differential risk of sudden cardiac death (SCD) associated with citalopram/escitalopram initiation vs. sertraline initiation in the presence and absence of PPI use among adults receiving hemodialysis. We studied 72 559 patients:14 983 (21%) citalopram/escitalopram initiators using a PPI; 26 503 (36%) citalopram/escitalopram initiators not using a PPI;10 779 (15%) sertraline initiators using a PPI; and 20 294 (28%) sertraline initiators not using a PPI (referent). The outcome of interest was 1-year SCD. We used inverse probability of treatment weighted survival models to estimate weighted hazard ratios (HRs) and 95% confidence intervals (CIs).

Results: Compared with sertraline initiators not using a PPI, citalopram/escitalopram initiators using a PPI had the numerically highest risk of SCD (HR [95% CI] = 1.31 [1.11-1.54]), followed by citalopram/escitalopram initiators not using a PPI (HR [95% CI] = 1.22 [1.06-1.41]). Sertraline initiators using a PPI had a similar risk of SCD compared with those not using a PPI (HR [95% CI] = 1.03 [0.85-1.26]).

Conclusions: Existing PPI use may elevate the risk of SCD associated with citalopram or escitalopram initiation among hemodialysis patients.

Keywords: USRDS; citalopram; escitalopram; hemodialysis; proton pump inhibitor; sudden cardiac death.

© 2022 John Wiley & Sons Ltd.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Study design
We determined if citalopram, escitalopram, and sertraline new-users were or were not using a PPI at the time of SSRI initiation by determining if they filled a prescription for a PPI that overlapped the index date.Abbreviations: PPI, proton pump inhibitor; SSRI, selective serotonin reuptake inhibitor; Rx, prescription.
Figure 2.
Figure 2.. Flow diagram depicting study cohort assembly
a To be included in the study, patients had to receive in-center hemodialysis during the 180-days prior to study medication initiation (i.e., the baseline period) and also have continuous Medicare Part A, B, and D coverage during this period.Abbreviations: PPI, proton pump inhibitor.
Figure 3.
Figure 3.. Association between SSRI–PPI exposure status and the 1-year risk of sudden cardiac death
An on-treatment analytic approach was used in all analyses. Fine and Gray proportional subdistribution hazards models were used to estimate hazard ratios, and inverse probability of treatment weighting was used for confounding control.Abbreviations: CI, confidence interval; cital/escital, citalopram or escitalopram; HR hazard ratio; PPI, proton pump inhibitor; ref., referent; sert, sertraline.
Figure 4.
Figure 4.. Association between SSRI–PPI exposure status and the 1-year risk of sudden cardiac death considering citalopram and escitalopram separately
An on-treatment analytic approach was used in all analyses. Fine and Gray proportional subdistribution hazards models were used to estimate hazard ratios, and inverse probability of treatment weighting was used for confounding control.Abbreviations: CI, confidence interval; cital, citalopram; escital, escitalopram; HR hazard ratio; PPI, proton pump inhibitor; ref., referent; sert, sertraline.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. St Peter WL. Management of Polypharmacy in Dialysis Patients. Semin Dial 2015; 28: 427–432. - PubMed
    1. Frament J, Hall RK, Manley HJ. Medication Reconciliation: The Foundation of Medication Safety for Patients Requiring Dialysis. Am J Kidney Dis 2020; 76: 868–876. - PMC - PubMed
    1. Rama M, Viswanathan G, Acharya LD, et al. Assessment of Drug-Drug Interactions among Renal Failure Patients of Nephrology Ward in a South Indian Tertiary Care Hospital. Indian J Pharm Sci 2012; 74: 63–68. - PMC - PubMed
    1. Al-Ramahi R, Raddad AR, Rashed AO, et al. Evaluation of potential drug- drug interactions among Palestinian hemodialysis patients. BMC Nephrol 2016; 17: 96. - PMC - PubMed
    1. Sommer J, Seeling A, Rupprecht H. Adverse Drug Events in Patients with Chronic Kidney Disease Associated with Multiple Drug Interactions and Polypharmacy. Drugs Aging 2020; 37: 359–372. - PubMed

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full text links
Wiley full text link Wiley Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp